Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418

Benzinga Newsdesk www.benzinga.com Positive 83.7%

Neg 0% Neu 0% Pos 83.7%

Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $416 to $418.